NCT01587040 2022-04-19
Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen
Sanofi
Phase 1/2 Completed
Clinical Trials
4 trialsNCT01943838 2016-04-22
A Study of the Safety and Pharmacokinetics of SAR245408 Tablets in Patients With Solid Tumors or Lymphoma
Sanofi
Phase 1 Completed
NCT01357330 2016-04-01
Oral SAR245408 (XL147) and Oral MSC1936369B in Patients With Locally Advanced or Metastatic Solid Tumors
Sanofi
Phase 1 Completed
NCT01392924 2014-12-03
Safety and Pharmacokinetics of SAR245408 Daily Oral in Patients With Solid Tumors
Sanofi
Phase 1 Completed